Skip to main content
Print Page    E-mail Page    RSS    E-mail Alerts    Tearsheet 

2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014 | 2013
04/17/18Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that new preclinical data supporting the development of microbiome therapeutics for immuno-oncology (leveraging gut microbiota to impact tumor immunotherapy)1 will be presented today by Sceneay et al in the late breaking poster session at the 2018 American Association for Cancer Research Annual Meeting (AACR) in Chicago. The data presen... 
 Printer Friendly Version
03/09/18Seres Therapeutics to Present at Two Upcoming March Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 9, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: The 38th Annual Cowen & Co. Health Care Conference: a corporate overview will be presented on Wednesday, March 14 at 10:40 a.m. ET in Boston, MA. Oppenheimer's 28th Annual Healthcare Conference: a corporate overview wil... 
 Printer Friendly Version
03/08/18Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
- Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phase 1b study data obtained for SER-262, the first ever rationally-designed fermented microbiome therapeutic candidate evaluated in humans– - Collaboration with MD Anderson and Parker Institute intends to initiate clinical study in 2018 to evaluate microbiome therapeutic... 
 Printer Friendly Version
03/02/18Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on March 8, 2018 at 8:00 a.m. ET to discuss fourth quarter 2017 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 5092388. To joi... 
 Printer Friendly Version
01/31/18Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2018-- Seres Therapeutics, Inc., (NASDAQ:MCRB) today announced the appointment of Eric D. Shaff to the additional role of Chief Operating Officer. Mr. Shaff has been Executive Vice President and Chief Financial Officer since joining the Company in November 2014, and he will continue to retain both positions. Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres, commented: “Eric h... 
 Printer Friendly Version
01/04/18Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis
- Microbiome analyses demonstrate engraftment of SER-287-derived bacteria; microbiome compositional changes correlate with clinical remission - - SER-287 engraftment maintained four weeks after completion of dosing - - Company to discuss proposed SER-287 development plan with FDA and intends to initiate next clinical trial in mid-2018 - - FDA granted SER-287 Orphan Drug designation for treatment of pediatric UC patie... 
 Printer Friendly Version
01/04/18Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Thursday, January 11 at 8:30 a.m. PT. A live audio webcast of the presentation and breakout question and answer session will be available under the “Investors and Media” section of Seres’ website. A replay of the presentation will become av... 
 Printer Friendly Version